« Back
Home /
Gemcitabine HCl

Gemcitabine HCl

Item no.	S1149-10000
Manufacturer	Selleckchem
CASRN	122111-03-9
Amount	10 g
Quantity options	100 mg 1 g 10 g 10 mM/1 ml 25 mg 300 mg 5 mg 5 g
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Pancreatic Cancer
Type	Inhibitors
Specific against	other
Smiles	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NSC 613327 HCl,LY-188011 HCl
Similar products	Gemcitabine
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	299, 66
Administration	Administered via i.p.
Animal Models	Athymic nude mice with MIA PaCa-2 cells
Cell lines	BxPC-3, MIA PaCa-2, and PANC-1 cells
Clinical Trials	Gemcitabine plus PEGPH20 has entered in a phase II clinical trial in the treatmentof the stage IV pancreatic cancer.
Concentrations	0.2 uM
Dosages	50 mg/kg or 100 mg/kg
Formulation	Phosphate-buffered saline
IC50	50 nM, 50 nM, 50 nM, 50 nM, 50 nM, 50 nM
In vitro	Gemcitabine induced NF-kappaB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-kappaB inhibitor IkappaBalpha in BxPC-3 and PANC-1 cells. Treatment of BxPC-3 cells with low dose Gemcitabine for 48 hours results in a dose-dependent increase in NF-kappaB binding. In contrast, NF-kappaB DNA binding is decreased in BxPC-3 cells treated with the higher Gemcitabine doses for 48 h, however, 24-h treatment with these higher doses increases NF-kappaB binding in BxPC-3 cells [2]
In vivo	Intratumoral NF-kappaB activity is significantly elevated (1.3- to 1.8-fold) in the Gemcitabine-treated mice compared to the PBS-treated mice, suggesting that Gemcitabine also induces NF-kappaB activation. [2]
Incubation Time	24 hours or 48 hours
Method	BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded in a 96-well plate. After 24 hours, cells are treated with vehicle, DMAPT and/or Gemcitabine for an additional 24 hours or 48 hours. Apoptosis is quantified using the Cell Death Detection ELISA to detect the amount of cytoplasmic histone-associated DNA fragments and expressed relative to vehicle-treated cells.
Solubility (25C)	DMSO <1 mg/mL, Water 23 mg/mL, Ethanol <1 mg/mL
Information	Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.
Chemical Name	4-amino-1-((2R, 4R, 5R)-3, 3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one hydrochloride
Features	Gemcitabine has been used for pancreatic cancer as the most effective anticancer drug.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S1149-10000-datasheet.pdf

S1149-10000-safety-datasheet.pdf